

Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Gérard Lizard¹

¹ Université de Bourgogne

Potential competing interests: No potential competing interests to declare.

The study by Ana Silva et al. shows several data, which constitute preliminary proofs of concept both in vitro and in vivo, supporting that eugenol could be efficient in the treatment of Alzheimer's disease. Eugenol could be efficient, at least in part, via the Nrf2 signalling pathway. Data comparing dimethyl fumarate and eugenol, could be of interest in additional studies.